Karyopharm Therapeutics Inc KPTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
-
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
-
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
-
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
-
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
-
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Trading Information
- Previous Close Price
- $10.05
- Day Range
- $9.82–10.17
- 52-Week Range
- $3.65–10.99
- Bid/Ask
- $9.00 / $10.28
- Shares Outstanding
- 22.66M
- Market Cap
- $226.86M
- Volume/Avg
- 4 / 454,593
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 228
- Website
- https://www.karyopharm.com
Valuation
|
Metric
|
KPTI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.99 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KPTI
|
|---|---|
Quick Ratio | 0.97 |
Current Ratio | 1.08 |
Interest Coverage | −3.16 |
Quick Ratio
KPTI
Profitability
|
Metric
|
KPTI
|
|---|---|
Return on Assets (Normalized) | −116.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KPTI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&^VXJ<> | LOCK|&FK$h | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!$g>f% | LOCK|#?>s | $69B | |||
| argenx SE ADR
ARGX
| LOCK|k$#f#p | LOCK|B? | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|g@pvQ@R | LOCK|NQQ# | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zBfKsjy | LOCK|&gY | $36B | |||
| Moderna Inc
MRNA
| LOCK|&%&tRk | LOCK|>v | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G<x>M<<! | LOCK|?!c%s | $25B | |||
| Incyte Corp
INCY
| LOCK|CrfPq@% | LOCK|?^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@Cw&<SR | LOCK|<S | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!%c?l@ | LOCK|ph | $16B |
United States